Industry Overview - The cannabis industry is entering a critical growth phase, with 2026 positioned as a pivotal year for long-term investors in marijuana stocks [1] - The legal cannabis market is showing signs of structural improvement driven by policy reform, consolidation, and expanding global demand [1][2] Regulatory Developments - A significant development is the U.S. federal government's move to reschedule marijuana, which is expected to lead to meaningful improvements in profitability for top marijuana stocks [2] - Reduced tax pressure and enhanced transparency are making cannabis stocks more attractive to institutional investors [3] Company Highlights - **Trulieve Cannabis Corp.**: Operates as a cannabis retailer, cultivating, processing, and distributing cannabis products. The company welcomed the reclassification of marijuana to Schedule III under the Controlled Substances Act [4][5] - **Curaleaf Holdings, Inc.**: Produces and distributes cannabis products in the U.S. and internationally. Recently relocated its Bradford, Pennsylvania dispensary to a new expanded location in Erie, maintaining a footprint of 18 stores in Pennsylvania and 159 locations nationwide [6][8] - **Cresco Labs Inc.**: Cultivates, manufactures, and sells retail and medical cannabis products in the U.S. and Germany. The CEO highlighted the rescheduling of cannabis as a cultural turning point, reflecting the support of nearly 90% of Americans for some form of cannabis legalization [10]

Core Insights - Marijuana stocks are gaining attention due to President Trump's recent promotion of hemp-derived CBD for seniors, suggesting potential inclusion under Medicare [1][2] - Trump is considering reclassifying marijuana at the federal level, which could impact its legal status and market dynamics [2][4] Market Reaction - Following Trump's video, marijuana stocks experienced significant gains: Canopy Growth rose by 18%, Aurora Cannabis by 25%, Cronos Group by 15%, and Tilray Brands surged by 42% [3] - While some stocks like Cronos and Canopy Growth have retraced their gains, Tilray and Aurora continue to show positive momentum [3] Market Outlook - Grand View Research projects the U.S. cannabis market to grow from $38.5 billion in 2024 to $74 billion by 2030, indicating a compound annual growth rate of 11.51% [5] - The market remains challenging due to low market capitalizations of some companies, such as Aurora Cannabis with a market cap of $329 million [5] Investment Options - For investors with a strong risk tolerance, marijuana-themed exchange-traded funds (ETFs) may be preferable to individual stocks [6] - The Amplify Alternative Harvest ETF has performed well, with a 17.2% gain over the last week, while the Amplify Seymour Cannabis ETF gained 12.2% [6]

Industry Overview - The cannabis industry has experienced significant volatility, leading to concerns among investors, but there is potential for recovery and long-term gains [1][2] - Regulatory reforms and market changes are expected to improve trading conditions, particularly with banking reforms [3] Company Highlights - **Planet 13 Holdings Inc.**: Engages in cultivating and providing cannabis products for medical and retail markets in the U.S. Recently entered a partnership with Ovation Science Inc. to introduce topical cannabis products in Florida [4][6] - **FLUENT Corp**: Cultivates and sells medical cannabis products across several states including Florida and New York. Announced a share debt settlement involving the issuance of 2,750,000 common shares to settle US$137,500 in director fees [7][10][11] - **Ascend Wellness Holdings, Inc.**: Focuses on the cultivation and distribution of cannabis consumer packaged goods. Recently launched a revamped eCommerce ecosystem aimed at enhancing customer experience and loyalty [8][12]